Compare Gold Fields Limited (GFI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Merck & Co., Inc. — how do they compare? Gold Fields Limited trades at $32.24 (market cap $29.07B), while Merck & Co., Inc. trades at $127.96 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 10.5× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (7.03%). Which is the better fit depends on your goals.
| GFI | MRK | |
|---|---|---|
Market Cap | $29.07B | $305.29B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $129.52 |
52-Week Low | $23.95 | $77.60 |
Enterprise Value | $30.51B | $348.71B |
Dividend Yield | 7.03% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $32.28, down 3.15% today, amid a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 40.76% net income margin and 52.33% ROE, while valuation ratios like P/E of 8.37 suggest undervaluation. Recent earnings were mixed, with a Q1 2025 beat but Q2 and Q4 2025 misses, and cash flow trends improved significantly in 2025 projections. News highlights operational challenges from inflation and geopolitical factors, though long-term value arguments persist.
The outlook balances deep value against near-term headwinds. Analyst consensus leans bullish with a $52.75 price target, but technical weakness and cost pressures pose risks. Investment appeal hinges on execution of production targets and gold price stability, with high ROE supporting shareholder returns.
MRK trades at $127.65, up 5.67% today, reflecting strong momentum. The stock shows a bullish technical signal with moving averages supporting the uptrend. Fundamentally, the company reported robust 2025 results with revenue of $65.01B and net income of $18.25B, and recently announced the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline. Analyst consensus is strongly positive with a $137.30 price target.
The outlook for MRK is favorable, driven by earnings beats, strategic acquisitions, and solid profitability. Key risks include rising debt levels and competitive pressures in the pharmaceutical sector. The stock presents a growth opportunity with upside to the consensus target, though investors should monitor integration of new acquisitions and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
